0001437749-22-012086.txt : 20220512 0001437749-22-012086.hdr.sgml : 20220512 20220512142631 ACCESSION NUMBER: 0001437749-22-012086 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220511 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTEGRATED BIOPHARMA INC CENTRAL INDEX KEY: 0001016504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222407475 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31668 FILM NUMBER: 22917211 BUSINESS ADDRESS: STREET 1: 225 LONG AVENUE STREET 2: BUILDING 15 CITY: HILLSIDE STATE: NJ ZIP: 07205 BUSINESS PHONE: 9739260816 MAIL ADDRESS: STREET 1: 225 LONG AVENUE STREET 2: BUILDING 15 CITY: HILLSIDE STATE: NJ ZIP: 07205 FORMER COMPANY: FORMER CONFORMED NAME: INTEGRATED HEALTH TECHNOLOGIES INC DATE OF NAME CHANGE: 20020912 FORMER COMPANY: FORMER CONFORMED NAME: CHEM INTERNATIONAL INC DATE OF NAME CHANGE: 19960716 8-K 1 inbp20220511_8k.htm FORM 8-K inbp20190913_8k.htm
false 0001016504 0001016504 2022-05-12 2022-05-12
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
_________________
 
FORM 8-K
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
 
May 11, 2022
 
________________
 
INTEGRATED BIOPHARMA, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
Delaware
(STATE OR OTHER JURISDICTION OF INCORPORATION)
 
               
   001-31668
 22-2407475
(COMMISSION FILE NUMBER)
(I.R.S. EMPLOYER IDENTIFICATION NO.)
 
225 Long Avenue
Hillside, New Jersey 07205
 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
 
(973) 926-0816
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
 
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
None
None
None
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     
 
 
 
 
 

 
 
 
Item 2.02. Results of Operations and Financial Condition.
 
On May 12, 2022, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.
 
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
 
Item 5.05. Amendments to or changes to the Company's Code of Ethics.
 
On May 11, 2022, the Company updated its Code of Conduct and Ethics Policy in order to include new sections, including, but not limited to Foreign Corrupt Practices and Anti-Bribery Provisions as well as updating other sections contained within the policy.  The updated policy is filed as Exhibit 14.1 hereto and is hereby incorporated by reference into this Item 5.05.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:
 
 
14.1   Code of Conduct and Ethics
99.1
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-1-

 
 
 
 
EXHIBIT INDEX
 
     
Exhibit
  
Description
   
14.1   Code of Conduct
99.1
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2-

 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  INTEGRATED BIOPHARMA, INC.
   
Date: May 12, 2022
By:     /s/ Dina L Masi
 
           Dina L Masi
 
           Chief Financial Officer
 
                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-3-
EX-14.1 2 ex_374257.htm EXHIBIT 14.1 CODE OF CONDUCT ex_374257.htm
 
 

 

Integrated BioPharma, Inc. & its subsidiaries

 

Code of Conduct and Ethics

 

The following Code of Conduct and Ethics Policy applies to all agents, employees, directors, contractors, interns and volunteers of Integrated BioPharma, Inc., and its subsidiaries, referred to as “members”.

 

The Company is committed to a work environment that prohibits human trafficking, illegal or harmful child labor, compulsory, prison, forced or slave labor ("Human Trafficking and Slavery") and physical abuse of workers; and expects its suppliers to comply, at a minimum, with the applicable labor and environmental laws and regulations of the country where the materials and products are produced.

 

Integrated BioPharma, Inc.’s foundation is based upon the trust which our clients and employees have in the performance and integrity of the company. Such trust depends on the personal conduct and capability of our members and their desire to jointly create value for our clients, business partners and shareholders. The following principles represent the minimum standard for our agents and staff.

 

Conduct of Business

 

Members will be held accountable for abiding by the company’s policy of conduct, as follows:

 

Compliance with the law: The company, its employees and directors must comply with all applicable laws, rules, and regulations when conducting business. Equally important, in their private life, members are responsible for taking care to conduct themselves in a manner that does not bring Integrated BioPharma, Inc. into disrepute.

 

Ethical Standards: The company and members must conduct themselves with honesty, fairness, dignity, and integrity in all their dealings as representatives of the company, and are expected to avoid any conflict between private and business interests.

 

Financial Reporting & Internal Controls

 

Integrated BioPharma, Inc. provides accurate, timely, and understandable financial statements. This is required by all who are responsible for the company’s and/or its subsidiary’s finance, control, and accounting functions. Internal accounting controls have been established to manage the company’s financial transactions. Strict compliance with the company’s established accounting rules and controls is always required. These controls have been established to ensure, to the greatest extent feasible, that the company follows all accounting principles, guidelines of the Financial Accounting Standards Board, and the requirements of all applicable rules, laws, and regulations.  The books of account and financial records are designed to fairly reflect the transactions that they record.

 

 

Page 1

 

 

Foreign Corrupt Practices Act & Anti-bribery Provisions

 

The 1977 US Federal law of Foreign Corrupt Practices Act (FCPA) applies to US individuals, companies and businesses and their internationally held subsidiaries, which subsidiaries—depending on applicable jurisdiction—may be subject to additional, comparable anticorruption legislation, such as the UK Bribery Act.  The FCPA, in particular, includes anti-bribery provisions and accounting and recordkeeping requirements.  In general, the anti-bribery provisions of the FCPA prohibit payment of a bribe to one or more foreign officials or one or more foreign political parties, party officials or candidates for political office. In addition to the FCPA’s prohibition on bribing foreign political persons and parties, the US has separate anticorruption laws that apply to activities within the US between US political persons or parties and US individuals, companies and businesses.

 

Bribery is the offering, giving, or receiving of anything of value with the intention of inducing a person to act or to reward a person for having acted. Items of value can include, but are not limited to:

 

 

cash and cash equivalents;

 

 

gifts, meals, entertainment, and travel;

 

 

political contributions;

 

 

charitable donations; and/or

 

 

job offers;

 

Corruption includes the solicitation of a bribe, whether coupled with a threat of demand if refused or not. The company does not tolerate any form of bribery or corruption. Nevertheless, situations may arise which do not constitute corruption or bribery but may, nonetheless, compromise the judgement of our members, clients, and business. Members are prohibited from accepting any gift that may influence their judgment on company matters as it pertains to the donor.

 

The company has established a system of internal controls for recording, authorizing, and executing transactions involving assets and liabilities.  Below is a summary of some of the pertinent policies and controls.

 

 

Compliance – No officer, director, employee, or agent of the company shall engage in any activity that bypasses the company’s systems of internal control or misrepresents or omits data from financial reports.

 

 

Illegal Payments - No member, or agent of the company shall offer or accept an illegal payment or contribution of any kind.

 

 

Cash Disbursement – No checks shall be made out to "cash" without prior written approval of the CFO. All nominal cash disbursements from petty cash must be recorded in the petty cash account.

 

 

Personal Expenses Using Company Assets – Personal use of company funds, including but not limited to, via a company credit card held by a member, is prohibited

 

 

Reporting – Any member who believes they have uncovered an illegal transaction must report findings to the company President or CEO. After review, this individual will report findings to the Board. Once the Board has processed their review, they will report back to all parties involved, including the original reporter.

 

 

Page 2

 

Human Resources

 

The company recognizes that its employees are one of its greatest assets. The loyalty and hard work of the staff makes the company successful. Employees and directors are expected to hold themselves to the highest professional standards.

 

It is the company’s policy to provide a non-discriminatory work environment, maintain a safe and professional workplace, and compensate employees based on performance.

 

Non-Discrimination

 

Integrated BioPharma, Inc. does not tolerate discrimination or harassment in the workplace, based on criteria such as age, disability, ethnic origin, gender, race, political attitude, or workers’ representative activities, religion, or sexual orientation.

 

Sexual, racial, religious or any other types of harassment will not be tolerated. This includes but is not limited to slurs, insensitive jokes, and verbal or physical acts of aggression. Employees shall treat each other with mutual respect and fairness. All communications whether verbal, written or electronic shall be businesslike and free of illegal bias, prejudice, harassment and retaliation.

 

Fraternization and Supervisory Roles

 

Fraternization among employees of the same department is discouraged. Any personal relationship between staff members in a direct reporting line of supervision must be reported to Human Resources immediately and may be done annonymously. This is to protect the individuals and the company from any liabilities.

 

It is the supervisor or managers obligation to uphold the company’s code of conduct in their department. New hires will be required to abide by company’s code of ethics and conduct and it is their supervisor’s responsibility to inform Human Resources of any violations.

 

Substance Abuse

 

The Company does not tolerate illegal drug use or the abuse of alcohol or other legally controlled substances by its employees while at work, on the premises or while representing the company, whether off-site or on-site.  The company reserves the right to inspect personal belongings held on company premises.

 

 

Page 3

 

 

Any employee found to be under the influence of alcohol or drugs while on company property or during working hours is subject to disciplinary action. If suspicion of such behavior should arise, the company can send such employee for medical screening.

 

A medical screening for drugs may be included as a condition of employment. 

 

The unlawful use, sale, purchase, manufacture, distribution or dispensing of drugs that are illegal under US Federal regulation (for example, those on the DEA’s Schedule 1) or state regulation is subject to disciplinary action, including, but not limited to, a for-cause termination.

 

The company recognizes that substance abuse is a disease.  Employees who suffer from substance abuse are encouraged to seek help.  Results of any testing shall be confidential to the extent covered by applicable law.

 

Business Practices

 

Confidential Information

 

The safeguarding of client related data is an important foundation for the trust of our clients. Confidential and sensitive information and records of the company, be it of private or corporate or about the affairs of Integrated BioPharma, Inc. or its employees, must be kept secret in a suitable manner from colleagues who do not require such data to properly perform their tasks. This applies equally to third parties. If someone without clear authority consistently tries to obtain confidential information, the involved persons must notify the CEO or CFO. Integrated BioPharma, Inc. cooperates with all competent public and regulatory authorities.

 

No Insider Trading

 

The company prohibits any member from trading, either personally or on behalf of a client, on material nonpublic information, or communicating material nonpublic information to other persons in violation of the law. This conduct is frequently referred to as “insider trading”. The company’s policy applies to every member and extends to activities within and outside their duties for the company. Any questions regarding the company’s insider trading policy and procedures should be referred to the CEO, CFO or other appropriate officer.

 

The term “insider trading” is not defined in the federal securities laws, but generally is used to refer to the use of material nonpublic information to trade in securities (whether or not one is an “insider”) or to communications of material nonpublic information to others. While the law concerning insider trading fluctuates, it is generally understood that the law prohibits: (1) trading by an insider, while in possession of material nonpublic information; (2) trading by a non-insider, while in possession of material nonpublic information, where the information either was disclosed to the non-insider in violation of an insider’s duty to keep it confidential or was misappropriated; or (3) communicating material nonpublic information to others.

 

 

Page 4

 

Who is an Insider?

 

The concept of “insider” is broad and includes partners and employees of a company in addition to a person who enters into a special confidential relationship in the conduct of a business’ affairs and as a result is given access to information solely for that business’ purposes.

 

What is Material Information?

 

Trading on inside information is not a basis for liability unless the information is “material information”, which is generally defined as information for which there is a substantial likelihood that a reasonable investor would consider it important in making his or her investment decisions, or information that is reasonably certain to have a substantial effect on the price of a business’ securities. Information that members should consider material includes, but is not limited to: dividend changes, earnings estimates, changes in previously released earnings estimates, significant merger or acquisition proposals or agreements, major litigation, liquidation problems, and extraordinary management developments.

 

What is Nonpublic Information?

 

Information is nonpublic until it has been effectively communicated to the marketplace. To prove communication, one must demonstrate that the information is generally public. For example, information found in a report filed with the SEC, or appearing in a trade publication of general circulation or (inter)national stock market would be public.

 

Communication

 

All communications of Integrated BioPharma, Inc. are required to be full, fair, accurate, timely, and understandable.

 

The company permits only authorized spokespersons to disseminate information to the public concerning Integrated BioPharma, Inc. If a member appears in public or takes part in public discussion in a manner that the public may consider them as a representative of Integrated BioPharma, Inc., without prior written authorization to speak on behalf of the company, then such member must make it clear that they are acting as a private person in their personal capacity.

 

Client Information and Advice

 

Members must not seek to mislead the market or clients in any manner. When working with a client, appropriate care shall be taken that the client receives information which is necessary for a reasonable decision by the client. This includes product information and advice given. Members shall not provide advice and/or recommendations regarding products in which they are not appropriately licensed to sell.

 

 

Page 5

 

 

Conflicts of Interest

 

Conflicts of interest can cast doubt on the integrity and professionalism of Integrated BioPharma, Inc. To prevent against possible reputational injury, potential conflicts of interests must be identified at the earliest reasonable opportunity. If they cannot be avoided, any conflict situation must be handled fairly as determined by the Board or a responsible officer of the company.

 

A conflict of interest occurs whenever one’s personal interests interfere in any way with one’s ability to perform one’s job objectively and in the best interests of the company. Members must therefore refrain from entering into relationships or transactions that might impair their judgment as to what advances the company and its business objectives. Even relationships that create the appearance of a conflict of interest should be avoided. In addition, conflicts of interest cannot be circumvented by acting through someone else, such as a friend or family member. Any member who is presented with a transaction or relationship that could create a conflict of interest must bring the transaction or relationship to the attention of their manager.

 

 

Acceptance of Gifts and other Benefits

 

The acceptance of gifts and entertainment by members (including their family members) may present a conflict of interest. While members are permitted to accept gifts of nominal value, they are prohibited from accepting anything that might influence their judgment on company matters affecting the donor or that might be accompanied by any express or implied understanding that the recipient is in any way obligated to take some action that would benefit the donor, to the detriment of the company, in exchange for the gift. Similarly, members may accept entertainment, but only as it is reasonable in the context of the business at hand and facilitates the company’s interests. When practical and appropriate, it is permissible to reciprocate hospitality. Members are strictly prohibited from soliciting gifts, gratuities, or business courtesies for the benefit of any family member or friend. When in doubt of whether a gift is appropriate, ask your supervisor. Employees will be reimbursed for reasonable, documented business-related expense.

 

Complaints Management

 

Integrated BioPharma, Inc. must handel complaints from all clients or former clients promptly and fairly and in accordance with applicable laws and regulations. Members are required to cooperate with any requests for statements or documentation from verified clients or former clients.

 

Gratuities to Representatives of Public Institutions & Political Participation

 

Holders of public offices, representatives of public institutions, members of public services, or authorities and politicians are mandated with the pursuit of public welfare. They should therefore not receive gifts, invitations, or other gratuities which might put their independence from business interests into question. Before making any payment, or giving anything of value, to a government official, members should consult with the company’s General Counsel.

 

 

Page 6

 

 

As per US Federal and state laws, the Company shall not contribute to political candidates or officeholders. As members of the Company, it is your basic right to participate in political processes. It is important to remember that members shall not represent the Company in any political, government or legislative capacity without consent of the Upper Management and or the Board. Personal contributions to political parties at any level will not and cannot be reimbursed using corporate funds.

 

Protection of Company Assets

 

Safeguarding the company’s assets is the responsibility of all members. Theft, carelessness, and waste have a direct impact on the company’s profitability. Assets should be used efficiently and members should maintain such assets with care and respect, while guarding against waste and abuse. Look for opportunities to improve performance while reducing costs. The use of company time, materials, assets, or facilities for purposes unrelated to the company’s business, or the removal or borrowing of company property, is prohibited, except where such use or removal is for purposes of supporting the occasional community service activity that has been endorsed by the company and where such use or removal has been approved by a supervisor. For the purposes described in this paragraph, the company’s assets include, but are not limited to: cash, inventory, equipment, computer software, computer data, vehicles, records or reports, non-public information, intellectual property, or other sensitive information or materials, as well as telephone, voicemail, or email communication.

 

Communication and Information Systems Use

 

The company’s communication and information systems (including telephone, fax, photocopy machine, voice mail, email, computers, laptops, computer files, Internet, and Intranet systems) are provided for business purposes only and are company property; meaning, the information, files, messages, and data created, stored, transmitted, or received using company equipment are also company property and may be intercepted, monitored, read, reviewed, copied, or disclosed as business needs require.  

 

The use of communication resources must conform to all company policies and work rules. Improper use of systems and equipment may subject an employee to loss of communication privileges and corrective action, up to and including for-cause termination.

 

   Prevention of Money Laundering and Illegal Activities

 

Integrated BioPharma, Inc. is fully committed to the international fight against money laundering and the financing of terrorism and applies a risk-based, “know-your-client” policy in line with applicable laws and regulations. Members must neither be engaged in nor tolerate any illegal activity in connection with Integrated BioPharma, Inc. in their workplace. This applies in particular to any infringement of anti-trust regulations and any support of tax evasion, including but not limited to, any kind of complicity in tax fraud.

 

 

 

 

Page 7

 

 

Consequences of Non-Compliance

 

Failure to comply can expose members and Integrated BioPharma, Inc. to reputational as well as legal and regulatory sanctions. Disciplinary proceedings by a regulatory body in the case of severe compliance misconduct may result in a reprimand, fine, withdrawal, or suspension of authorization to conduct business either for the entire unit or members. In addition, failure to comply, which constitutes a breach of members contractual obligations, may result in disciplinary actions from Integrated BioPharma, Inc.

 

Protection of Members in Case of Communication about Illegal or Questionable Activities

 

If a member becomes aware of any illegal or questionable activity in Integrated BioPharma, Inc., they shall inform a company principal (President, CFO and/or CEO). No member who communicates a bona-fide concern, shall be exposed to retaliation based on this communication, even if the concern eventually proves to be unfounded. Such communications may be made anonymously.

 

Ethical Conduct of Business

 

The goals of this Code can only be achieved with the contribution of all. It is everyone’s personal responsibility to adhere to this Code of Conduct. All members are encouraged to contact their agency principal upon detecting that someone has acted improperly. This step can help to prevent small issues leading to big problems.

 

 

 

 

Page 8

 

Page 9
EX-99.1 3 ex_374256.htm EXHIBIT 99.1 PRESS RELEASE ex_145031.htm

 

ibp_logo.jpg

 

 

 

NEWS RELEASE for May 12, 2022

 

Contact: Dina Masi, CFO

Integrated BioPharma, Inc.

investors@ibiopharma.com

              888.319.6962

 

 

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2022

 

HILLSIDE, NEW JERSEY (May 12, 2022) - Integrated BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the fiscal quarter ended March 31, 2022.

 

Revenue for the three-month period ended March 31, 2022 was $15.6 million compared to $17.1 million, for the three-month period ended March 31, 2021, a decrease of $1.5 million or 8.4%.  The Company had operating income for the three-month periods ended March 31, 2022 and 2021 of $1.0 million and $1.7 million respectively.

 

Revenue for the nine-month period ended March 31, 2022 was $43.0 million compared to $46.5 million for the nine-month period ended March 31, 2021, a decrease of $3.5 million or 7.6%.  The Company had operating income for the nine-month period ended March 31, 2022 of $2.3 million compared to operating income of $4.5 million for the nine-month period ended March 31, 2021.

 

For the three-month period ended March 31, 2022, the Company had net income of $0.8 million or $0.03 per share of common stock, compared with net income of $1.2 million or $0.04 per share of common stock for the quarter ended March 31, 2021.  The Company’s diluted net income per share of common stock for the three-month periods ended March 31, 2022 and 2021 were $0.03 and $0.04 per share of common stock, respectively.

 

For the nine-month period ended March 31, 2022, the Company had net income of $2.3 million or $0.08 per share of common stock, compared with net income of $3.5 million or $0.12 per share of common stock for the nine months ended March 31, 2021.  The Company’s diluted net income per share of common stock for the nine months ended March 31, 2022 and 2021 were $0.07 and $0.11 per share of common stock, respectively.

 

“While our revenue decreased by approximately 8% in the nine-month period ended March 31, 2022 from nine-month period ended March 31, 2021, our revenue from our two largest customers in our Contract Manufacturing Segment remained consistent; representing approximately 91% and 92% of total revenue in the nine-month periods ended March 31, 2022 and 2021, respectively,” stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.  “Revenue in the nine-month period ended March 31, 2022 was lower than the nine-month period ended March 31, 2021 due to increased safety stock and consumer demands required by our customers during the height of the COVID-19 pandemic.  We also believe the fear of slowdowns in production due to the pandemic were contributing factors in our revenues for the nine-month period ended March 31, 2021”, the Co-CEO’s further stated.

 

 

 

 

 

A summary of our financial results for the three and nine months ended March 31, 2022 and 2021 follows:

 

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES

                         

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                         

(In thousands, except share and per share amounts)

                               

(Unaudited)

                                 
       

Three Months Ended

   

Nine Months Ended

 
       

March 31,

   

March 31,

 
       

2022

   

2021

   

2022

   

2021

 
                                     

Total revenue

  $ 15,634     $ 17,072     $ 42,979     $ 46,501  

Cost of sales

    13,652       14,411       37,823       39,293  

Gross profit

    1,982       2,661       5,156       7,208  

Selling and administrative expenses

    990       942       2,849       2,736  

Operating income

    992       1,719       2,307       4,472  

Other expense, net (1)

    (32 )     (13 )     (117 )     (169 )
                                     

Income before income taxes

    960       1,706       2,190       4,303  

Income tax benefit (expense), net

    (163 )     (465 )     154       (797 )

Net income

  $ 797     $ 1,241     $ 2,344     $ 3,506  
                                     

Net earnings per common share:

                               

Basic

  $ 0.03     $ 0.04     $ 0.08     $ 0.12  

Diluted

  $ 0.03     $ 0.04     $ 0.07     $ 0.11  

Weighted average common shares outstanding:

                               

Basic

    29,821,138       29,709,992       29,826,321       29,671,251  

Diluted

    32,360,398       32,863,632       32,413,829       32,445,415  
                                 

 

(1)  Includes interest expense of $30, $58, $104 and $213 and unrealized loss (gain) on investments, a non-cash item, of $(6), $22, $(48) and $(51), respectively.

 

 

About Integrated BioPharma Inc. (INBP)

 

Integrated BioPharma, Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at www.ibiopharma.com.

 

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” believes,” intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes.  INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include developments in the nutraceutical market and related products and services, risks associated with the outbreak and continuing spread of COVID-19, general economic uncertainties resulting from the war in Ukraine, the Company’s ability to maintain the qualitative and quantitative qualifications for continued inclusion on the OTCQX Best Market and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q.  Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

 

 

 
EX-101.SCH 4 inbp-20220512.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 5 inbp-20220512_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 inbp-20220512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 7 inbp-20220512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 ibp_logo.jpg begin 644 ibp_logo.jpg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htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
May 12, 2022
Document Information [Line Items]  
Entity, Registrant Name INTEGRATED BIOPHARMA, INC.
Document, Type 8-K
Document, Period End Date May 11, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-31668
Entity, Tax Identification Number 22-2407475
Entity, Address, Address Line One 225 Long Avenue
Entity, Address, City or Town Hillside
Entity, Address, State or Province NJ
Entity, Address, Postal Zip Code 07205
City Area Code 973
Local Phone Number 926-0816
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001016504
XML 10 inbp20220511_8k_htm.xml IDEA: XBRL DOCUMENT 0001016504 2022-05-12 2022-05-12 false 0001016504 8-K 2022-05-11 INTEGRATED BIOPHARMA, INC. DE 001-31668 22-2407475 225 Long Avenue Hillside NJ 07205 973 926-0816 false false false false false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 19 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.inbp.com/20220512/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports inbp20220511_8k.htm ex_374256.htm ex_374257.htm inbp-20220512.xsd inbp-20220512_def.xml inbp-20220512_lab.xml inbp-20220512_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "inbp20220511_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "inbp-20220512_def.xml" ] }, "inline": { "local": [ "inbp20220511_8k.htm" ] }, "labelLink": { "local": [ "inbp-20220512_lab.xml" ] }, "presentationLink": { "local": [ "inbp-20220512_pre.xml" ] }, "schema": { "local": [ "inbp-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 19, "memberCustom": 0, "memberStandard": 0, "nsprefix": "inbp", "nsuri": "http://www.inbp.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "inbp20220511_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.inbp.com/20220512/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "inbp20220511_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.inbp.com/20220512/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001437749-22-012086-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-012086-xbrl.zip M4$L#!!0 ( $]SK%1&!MD^L!, #\M 0 - 97A?,SU= MZW?B.++_//U7Z&:G9Y)S#,'F'=*81@()T #NB<[B3(LE2J^E6I'L(^[LJ>WSSN$NPUW_UT+*GT29-\_X]= M*A>*=AZN'A_&C7#U?W(Y](D$A&-)/-0:H/MN%'B$G[,>03>,2^RC'"H?VLZA M4W E&KKY@G*YYG&/2(S<+N:"R ][D6SG:GM):X![Y,->F_$>ECF/ M2.)*RH(]Y+) D@!Z2^*3L,L"\B%@>\UWQX>+D[L+Z,'1%SQ MF,AI;_' MAU%S5WES!BW8E4?HG 88N"*HA@Z9W8%)]2 M=@-VM8KY2KSB; M4^?62&E:6=/;9<=_/&))$3M!.:KFG6GZQQM>:Z9&H%L2@F(?/BMK!R% MWW]$F,.=Z * [X&&<[>+BO;0\CV#@PD%ZY+DY#13XS?&0^F1],<^YA2#9@?* MN?(;$Y3_'0E)VX-&LC+%X.'_FJ;CM\O/G^\NSR\L!/L$^M^+V[N+_T/[DUO$ M ?A[Z78([>]?WY_]\>\C='EU>G-P@/9EEZ!?_E%SG$+CC/5"' ST)[N!0"K) M!=4W:3U /)&>DE@;3''@4G R^80LU9!M*EQH_I:(E,P0Z1.C.,G'7Z<8^>LR MG!RS;2G8KUA6MZ1/@HB,6"*[G)!<#T;MHA" QKR9;$$/6*"?[7*^@H!*'YQN M\+E!,!QZ2@97JGE[>,5ZYN#P$R./N)Q@01!KPVCY\F@:&*J6+[W/QYR#4(*@ M!!*HBSW$0A5F@#N/:."J^")];C%[93CP-!7)S(71S.H"-%1'#0"G4$4(/ M=@TG 0V6ADFI.,'%1S I528D^ZRAGX*D^!@DU7SE^2!9I_@E::C\,O2G3!8/9SA)H4$M!>BDS M4?#Z\%LPX2S858>PL^V=A%WBG/[5I3XL.^*PTG@C'>Y=.B&*PY"S[[0'WK _ M0+7W()+G[$=MSGI+;YN31.@;58-\8,B'-4#,C5SP!0 /7"@JU$65U.#8E3!4 M$+7ACXBK_>V.='H0P\!@/0QS>RKK*JA0B=>&77[O09%W7FO M@""9U*YY3%':PA< [C&"K&%T(*2.+V)=SIUU*6FCB^_$C50_=-UN4U>M4U$Q MUA$+W=(^1G==$H+*>GJ.LRZ'E:F/Z7Y?G.;N.@"4P#'6'J_Z+(.P+AEK$I[#R.) BF*L;!:S(8P^!A@[( MW(MT0GY(LNHZ'"XV$2I1SVDKTC!1T&)CV"60$,_TF!+96R.I7UR/K%X[XM#* M$US,-32O:@2>EY0<.N.KK &X/A;BP][-I]/?]X8$/5!/=M4MA??#_$F.*TPD M-"9-*O43MZAZQJ/!KO[\,GNTF:F7(5%)&:'+A[>V&/<(/U+%$PZ=SYC/> /% MK3DP(QU86, "TD"/)HD!?(2<\'L#D.6KN@OOM/8+%E+_#AH O@[)M4!MON9P M6ZHIL/^ !P(&Q^[7#F=1X.5FW?EDI;^=WRY>J4Z23:WS[51-5@##$P1V"28< M*&.A=#P]-Z-=76W-EOP/^=IB$O87W5'U4SN26F;P8:^R-\O8OHSE>I)GYXR7989DX6/[%R]N M: %5_OCJ_N+3[WD]LN)A2ZOSO+HY.HG=Y?GER>WEQ M-\K,*I(/I3=B$/4^[.7!RZ)^_KRT AX-83D]I4^PES\MKW%&,>BU5C/C5/Y[ M>F+Q4S+B/N M:H;$O38>P&_>-/OQ>#\^N[XZO[BZ@^T8_KJ[_GQYKO?FNWOX]>7BZOX.77]$ MUS<7L&5?0@>S)YL]V>S)9D\V>[+9DS.Q)Q>W<$_>OU0Y;A8)E8^V$/GNDE F MU2"5OQG7AG"/18$4!_.WY5B+UKDKQUJTBAF7T:)2AK1H SPP+I%QB8Q+9%PB MXQ+MIDOD;*-+]&> (X]*XJ7[.FO..1A_ROA3QI\R_I3QIXP_9?RI[?.GUH&' M;9ECK$GG:]HG)XMR(W"?KV/KFGFT[Y%[O-ZO,<*_>WW^ZPO3Q[[TERUC\"]1 MJUNG6Q,#9$VF=C9 UF'],@B0*W4L\(?PL7II&=N\R[;YM1'_5/F&9Z%C$,T\ ML3S597A&61T7?7Q%+^ (">93;_-:/3K:^P/6/CE8.\JTV*]Y-O8-;@$&A^O$ M874S.#1;S=JVFC5E1R>3WF,57T?"3L MM^+(K"E+/!MRZTC<[@SD%ENY2C8@MV[?V=E\^F1+(;?8RKT=-WD&A)9K>EQ1 M7U@ 3^V0%*I3KX_*QPN_2;"P*CN?ACG71S7-!314%I<*Y],PY_JHT+: ANKB M^M5\&N9<'U5_?AAW*5]!=PHE"SG%&OPHEP]VXKCP_>03018< 1[[Z4/[^'X= M^Y;&RTKGGI5Q_WDV+I_2,?T@ OV%[M729I>M2K&4IAA 8L >. YAE^71D^^U MKYIQ<^U">8,06NG=R==F'>0%4!AS5%:[<+EJ5!@A2LO5JV:4WQ!U)$M\&]O*+(9\&<@ MK%DE^.N64T\%_Q+QTH;!;S+TSP^B/G$FA'K B&3@?A U06K=JHS8[X9L@&?/?.NM?("BH6J^2Y(AIS=S/ND>\V2 M54K_#IKY]L=;]Q+UZ]^3'+N% B+1L8C"%/[!8 U?O70^>;.X[0 @QS.'!?FL] M?I.E7PGH[9>$*)E!_=:&+"8_OQ+45U*S.5E,SQ^\7LR5DIDW#QLS#QO+P,/& M=B\C<*FK1:A%VHR3I':$)/Z^NR?P,A]X[S7KE9><9S,5I-VL(!52CP28"I*I M(,VN(-GI)V=-!2.?T7C%76KF*I;'HM:/FED^:4AJUSU M'(OR W%3T7SC?6L5X2V'4DNLVK::5<$(=4MVG3,FFU@&)+O.50\WWG5+=ITS)JY!!B2[^E6; M4V+/=6<>!S!U31=",)VK0ZVU_Q+/SB; M> @#JW"'/#K1(Q"+I) X4%(UQWO,\1YSO,<<[S''>\SQ'G.\YTT=[S&YY5T_ MWK/"F&%;G_VTS/?5ZE;-L2V[F%K#-2GES*24-Z0"6YY%!A6H%NK6G#=&FEQR M9G+)&U*!+4\?ZUV@8A6=U-2922)G)HF\(178\KPQJ$"E:EM.V62/=RA[;([P M9,:^;'F@572L8J5@%>LFT#*!UFX&6J "M4K1JJ2_>-0$6B;0VG85*-E%"+92 M7TUG BT3:&V]"I3*H :ICU]_DX'6R^M6R9K4C+"89+&%+ !:=FF0(M8Y#Y9> MLU78['0;> ?0#*(RKC89D).!A8'%YJ_U#GYC\"B;[]Z-<\?Q MS8D/NXX356':]*B:=^"G^LNNK)J:8Q&-:)A*^$L6-GP:D%Q7GY(^LAT V7B$ M4*KW?QT<'\((R:+09>#ZD0=TT$ 23H1$R;OG$&NCGXO@*/Y<_'6*B;^^TC'S)46^ M"=Q-CC\U\(2L]1#Z8Q]SB@-Y%##>PWYC@N"_(R%I>]!(EE5((*S^UV*H1%Y+052?T)NGTEZD\-?(%] M]>V%-NI3"<>9$K11Y]C+B$1IBU MK9:F;E-DX3Z$V,IP(BS1P\-#GK8H"S7M>9?UYNK6%LCLO@L\\)@;*%J)Y[@ ("EAX@ R:::J.+&%?2[\#.X!RP^W"( QC$Y[ MH4_AS]8 T.=VYS -T)?.T X)"-<380[$>M!(V\FXBL8'QCV!?OE'S7$*#;7U M )PM_=%N#)M!^M2E(8PYOM0B0%U_HD'M7X'WY%[8A&COT9W)!=%5W)IN?9C5 M"&H+(W0&T^VA#[8\:=)*3 '4F _YJ 291R<@W E^,*VF(-W@46L; 50EXVHS M1\IF:'9-]-!HB@7<(L@CT.S- [*B1PT1,(DZ$>; 0Q);F'8$!HF@D'!M*@". M>72G)#QQ-VR_^"MB@1*;&&J I^ /U!/6MF+RHM;?("^%*Q<6U"$Q%S1C]<0M MA4&-HB@$)6DK6(W\ A1&/ 38B?S0%5$8C0)/J<=7H#5@B+7\H8;!))STJ=#0 MCT)-# X&DU2K\543."9"\_Z^FVB>]5CM8NZ,U4TID?*"@*_@ ):FMX.A%8Y73WB?NDJS$Y47@KE4]U.V18\(.VJ+*P:K&Y15 MHD&DQ0>PP9YB]]GUOR[/%' M9:WM0NYW3055D(]:@GR+5.\_0%_ /@+XXQO$Y!U_#.%ZXH+A5;&1/[!B[+HX MT.JFN0?HXDJY8LU5L$S4"" 6*^C0J(ULX=Q]"5:!9@+^Y"E+75[ M8O@>['=(, L]Z.T'Q*X45.TA>H@N!MH2"4UL#PRL02)6&+!- Z ^&,_?.@7K,H5]V@?N3Y(^,/>YY.[^]S-R:>+W.GMQ\U'5V\^ M?;R_G6KKMG.=U?V_.;_ U!+ M P04 " !/MS M'+>1_QS_%3BFSI&JEM3#<62+%*\HFG)4\8-GR74?K[ SV%V(\S(PL]3FK[]^ M 8.97=)4K(R.C_]XD\GK6T+_^]7 MS_[Z].MG1_#7DT?\(?SU/PX/U?>F,DZW)E?SC7J[ZJKE*;5*EMIYTW[XJ!K%X??',BG ME2[-BX-%[4K='N:F-5EKZ^I 9775F@J^W9K"-*NZ,B^J^N#TBY-'O.23>9UO ME&\W!3U>M8?>_M,\AZF;]EC1!PM=VF+S7'WY6U>WQV]M:;SZR5RK7^I25_SA ML6ITGMMJ^5P]MI5Z?/3$5L^*?2&/G\BG^%B>1M&:TS^CB\' M3\#+R8C]K_O:/W#6DB4,BBN?J M7>=;N]C\WE:>U[E1]4*=UU7>9:W25:XNVI7-/I<]NW%[=N[FP>G;E8&1BJ*^ M!HFK;MX^N%(*FVT4"AB@0-762A>% A8'F3!3IFR*>F,,_)A;!Q=&[>!'%%5. MRR\6J-Q5GL9=OGCY]?'QB M3TM3SF'4DT?VE#Y\%GM<.J:-LN@)N]$17^BUX:^J!P=_I^'?]L,38;S! M[[C-P4/ZK5EMO,U@0CWO/)$Q+AJHX9C^;-XW0)=>J(G(V!$=XSH*6 .\CU:E MK6S9E3-U;=L5O*1ABL_PJI75T&#]3L"$A;YFNG9FV14:M24B;'P\JX'2W49= MKXPS] EH50;.JN!'8 N1U> 7^#/_8O*):.](M#>+#F3_)\^./4P$>C&="9+U M7'OX;M? ;W@6K8.AX&QLME)UYU0&5%&U?#)1I@'Y BE:?J(QCC3C*C,LG&@% MMMWT!TX\=*3>=# H3Y";QE0YT$0< Z@=""=+Y&RF&SVWA8R$BQ%A1G^%QZR# M<;Q%*JK5NQHF+C8J7JUUT:$@=^E;S!0P@JV,]Z!2@_H5QO*P3695%V M M^",UO & $:O,-@6\M3.@R7GF=1,8 TX>AM NCY/Q%< #M\"?]TB[^ZV9\%'# MV;X,IS+I)#N9^D>A^VNX0=3L;5E=@ MMX7'9J@H,)W[YY-XO=M)$-V"&+0D[N*5"/?=K->HUK7%:C=C6]2N#JK<(QTY,(_1^KBMPX& GVE;-#C4;4S M$=,@*T&2K5$T%G9A9KTL!?$)4@WDO[>!E%I-&D6F6;0&H0S#E-X4:W@9&!14 M UV!"&7%)Z_ATZINU=SAH[=8<""F:]@(#]*T:\UTL=^=\LCP@$ORC=PX?HOF MB%+"R0J);9T=D1LZJ^#50,'4UB'MH)VRK"Q^-+S%\:B!-L-]"PNKEAYE1[P. M@2IQW.%US\,@!;&>*7KSNK;P*:P4%K8 8@>",>VU 7H.Y(F/Q6N:;"18J)_H MY.YT\LI6()Y H5:_&!0#R)#L-WE-)B?\X1P-T;JX9R? Q[6SM\@T,%/6-D]JG<+ MZ1V7/,SP"/XT\ _T?^5YC;@AZD)8E/4()))%5Y%G&U83*27YLSPFZO\6<_Z1Z*$5R]K^&<6+)[P.D0R.,)(:Q!]@96'D=9P MQ&Q%U\6\KJ_X>9Z3OMN?$"@I-4Z.9(<6UK+BK<&[ I0+9Q:%X3ME<)AQ1S8R MPOT([6_V4K+<=544T2BT]R\.+K]_^8^#L,AKF[_C S0'V7W__TZX]]Z ,T MCSZDL3/P$<,<.]:"+W33+M_E@ Y.::HG$B49_O/%RO;WXY;G(BV-@#0?"&L^R,H--.0:SBW?W:?/^&)B^P/#;GQ_3?^ YG5TM M';I6#H=_VCJ(OW^W^R#XY?_%8WC[\_D/MKK:.? VI>W8G=L#2[?M^DS1QS/E MC;.+'<>7L,/^,.;^KP0UN=H!S56@KCG7@1"YQ."!S6#>,Y"_K-.=P95Q"%87 M<-X&O@"*B"=A_$>K=ONSH7?V[C_Y]MDS]>L;]H/^(ACD'5W8H$GFN>5999V.GH6MM!F_+OJ% M"[.TGO4&8&MTVVI/U_VO_U OA=1@+U*5 G>%G WH6;49:!T.?\V*CO3BE$B; MGDA'"BBK+*@Z7!G3D'*7*#QANM>56E*B1S'C@,0-@P<-"U86 S.PO V%:U#Y M4?00;@L(>XRQE'#RJ%S3\=<86J&P!#IV=WP!76HM6>3TSGAH^,-F^&0&+V5S MU"%);>\?HF\95+7CJ02E$Y?<>^YDZ?AW^"^NF93U[560%UVB*&%%=&IO0-T% MD\#@<;?;IXW1&M+=*%N"R 2H:&UQ!%+'Q=4/XP1K'7[E-=R5+R;; M_HXR*[">968$ C*.(HM+V&3\%PX V,?0;T3AU08/CW[FB$@TKBPES1!-+?"8 MNHP84,Y2: 'A)^!ED[J8OH^HQ<99^6 M3O>G+_[TIY/6P0_X;S[6^N^P[C8?/[PVCOA3GFGKYEC6]XU,"E^_7]W@S]_^ M[=FWO.FXF+N]Q#ZL/--^)5%*^ $O*:!\O*2V7@;^Q6,%!9N(:K_TL8G.)SJ_ M=>5+N\"X>6GH!B=70:LMY7F(5\KIM2DFJI^H_A.B^EZU)7^Q!14&+8J)RBY34[(S@U\%'M)DJ?*/W3H?1W]9RMY8],A.^/Z^&\=Q=%IQZZ M$3RFE=E6!T^"^-30?6G@[P[3?9L"+'Y. 2;@G2X,@7EM7C;=I(XA?Y0V EO MQ+N:US0V7/+PGFW7FF08'#2,CRX,>/9D?CHCOSH&A^+XN%17ES@J[LB[+E^: MX&),LE9G?19JZOXZ4C\FF5C!UP>[L8 QT3=J&G&-;A0JX^RHPQ>QU:+H#$;, MV:>,$_.\5=R^4K7=!S.MVUJ]K9?_(OE(EOLHY.>1!.M]6Z+MC+YKV1E.+" MY17.!X\$!M0!N4!AI5)1BX%39X<\SG\5$N,Q?5%6'UE%GG+*5=_E+F(Y0!%H4RUQ%P"3'_$ MQ$H.B&Q8_,XWC::(WJXT)98$?IWXL.LO$KA.[WKKRUU(&=\F16*\.%7 J:TF_QY2DQ--W2#%2&&>2X6)@UPV< M-A(&4U>VRB=&FACI$V*D+8[Q]9>M3';EA7?F6&F)Y>O?CY29S!(!;<576@X=Y[,[?GR M:DP+ER3]E>H/YD8T7Y/W!8/Q*Y+Z,?'EQ)>?$%]>AFK6B_>-J5!-_-4SF !? M96=LS0V8-3XCE=HQI[RK9SP7.80#P5+N').+L-J M@GC)6I]X&B;FFYCOTV&^I.0IY:\S=(81]5-!S=P4UJS9@-MP+4A7936\$SIS M>J4R\,2:4?1^IG\?#Q[^1Y M[-,',N9)/VHYO-8$A,2@_()"$SC[U*)D^% M"F63.;NDJYV?->[CNI7W9R6?0@7'TWNNX'@Z57!,%1P?Q(S"!%0VP> XOQA? M=R[[X]'!]G6+=H1XB6M))=+LH5,#6N":[% M!0Q)U0T1EN6/#6[L_]&_;D/Z^ T((;"I4LX,!@/(4$1&S)Q%LQ\.9;,%?#6# M66V%<46,/^F%"2A._5G@(TVAL?28PTXEVD48S.T)C7&(0,U*\(2FHQL7A/T$ MY_%=?QZHED[2[0,*];?3"?+A;C(V&T@W\J>)QRJAWTBF\!"AEL7R*%!;,,SD M!;-JIDR[JFPF>O4,2Y9RM+T=C=-G&.H64P]RCD<)0)OPY AB(ZG*0<0_>&VJ MST)L./.^(V YR]^MJXEU!BMY0QM$FV_I7]Z]C@)P>!W5E*S2;AJNS$]H@.PI M0K8QD6KR -<04F'0*V/]R#&C?-$QT",Z"^3,KZ MEW#1DO1,+T=VX[:40&,T K31HBFSINS:CFPWC]Q"PZ?F$U!HO[0;@#[4;'<P5R_>%,ZP4B*$\MQK+WYQY!Q8E$GBR M@US5AVBV$VGNE.JOD*81#Y8!"&S@8W0,1?A!$ O,'RO;Q%)'T6 E2XO4'%91Q5." M#A2$]*"D&SFVZ"^B^ ?Y4T@BC"P39%A6#UK _Y&4F 904*B[Y@RR."'-&=H'TYN?VBHUX9]9#A*TB @&T3CG<,C M.M3F=DTP0;:TYTR0@@/@5H1=ZVGOB-YD!;330_E%M!_TTLU1Z9YO;AS;,/*P MI&Y%H$P;7@)FZU\C/AV!@QA+$R:R%250CHE1(N5K6P?(F'TXHOTA%I#4;[HY M&I:946>(J3L)Y=M D[>5[: MY*Y;5*LW-#WBTU(H,), M8A_.P".O#-T5URN+: 8M*=*S""_K#*;GDK+'WXB*=?!^1]2ZH!C5BP7L2&NX M^)]^3.$.>N^)!WX3WP;Y;IG!6 V+%\O<%' [D7>?HG%)BFY8W,1LG[9+_:M[ M=JE_-;G4/RN7^J>Q E3/@WA7A%R.\G5N&%-15.!0!S&\0/"2"3?"0-[6F Y/ M12-Y1VBU>%G@ORM0A$C)3@!ST%BP#>CWF%;/D> C]1HU?=_83!(,R0H!G:=YK."7B MF=J;H+U]=]%C(;W)5B;O@*&?/"2_)^*GIL/\+N\F60^SG;E4&JGJ,-.HD((* M$!S#$S?>.8 8]7-1ZZDP"8[" !D%%?HBT=AKA>H/4 ;Y*\9/4PRP"OX:\JH: M),AO,-9<)[2W>N*^P=.(;N;Y G&CI>==KG<(EPNRSY98%$JD$)9 M4O7=#532RR9@8G.#&:F]E9+;(S4X"VK-$D,R-CF9'H!P&\\>]0L:."#5<]4Q M+$5^T7-*K4=_Q@*#+[_3RTL)4G?2*BRXC*^PML4;4'1:=CC[3H :I.<"BPU?XJ0(\'0$LC+21(4%H7H019 MZZU+@[[I4#60P0)<*&AMR4WC034PU(JG=0*06<\I/6 @AY-=GXD:SWF)$4V0 M-@/>""B$:Q N?J:L2BQ%N&57LQI?E? 68V,-RC@@@=]T$]NVO(DS92QY&H.3L-BPKY$, MR6+!: HLP,B3&=JDH1=&R'C 1"2.8I 73NGV!X@QDP50:"OZ_H/T0U6(Y4,, M;&"E#P@)YO'=C0>MT(N\:N@\F'I.QVE'"9XNHC?$+>/Z^):ZA>T$)L4O@"C" M"4/$I:._CYHD<*@/UNTY @[L+W?-KG#.Z WB*CFU*0,CQ%%$GBQ]BN/T^R#" M:H:BJO=D4TD57!UT67!9\B1KMG@(3:[;J2CD6>1F8:N^JFPA-B7P 47!)U*6".$:HI&AYR7Q!]^GV5P,505GDST( 8-",&$$B994QF^B;S! M0X%5':5DW&EZHB6XB_^'W%K"HSP.&B['JN'H"A'89"(ZD*$\S$LX:(SS76PGN1&K>_P[%Z\'0X(N48_GN# MSI)FDNE^B8"]UASS+VK?,V@RZY;@Z]\RR@.0*:02(2XU[N- EZEYCM+ZA,GS M8_S\P5@'/NYJD\A3O37>XX3_76*$_V!<:)/FEEMA1+R^:U@3R?= MZ?^ \)JH.^MX-D M.1T=NG;8D"#"OJ.3@>2=YR:.6F&6@V5XF_XV'"31B7:6]=4PF#5G.P5M" MS2#06>S(H4NZBETC&@&5BO292WQ3^KK M#E6\Q&49S1LTSE0(CY;B_Y.E$3< MIVFK?PQZ2>*I_,,9\:/&AQ.EM@[:XX!:Q6K16$%@V3@-:9FHB!=$X*NM9X2W MH]*8_%D8/72*&6CVP3A"W+]DP 4G0&74 L*9@!E'$1?B74<+4B!1N?I/S;'"0&M6%BS6*!@;Z8Y&4E!6!+$O2FVM' #\]0BI+8*[9\ M?*MDRUEVSG9G^3]7E(&+4?ULI:LE?M%H,L8((]"6;'S)'\FVP8)MRNM%86FH MI&37(]AYSR[ <*APF6X9H(]^ZZQG\8S61NVETXQ>.L-8+!BM?4<4UDKVZ@Q^ MAL?$5PZ/P8&6/L /@CU&X(08)^745SFKM2GJAIOO3&+@@T7J3]'"FV3JO]IS M=21!PX9BPZ@")0_B(7 ;3Y(&H"]0MFBPN'N#'Z:^,BV5<1VIMUSD:(8^F!EY M;BCND)L206$IM!-](R/9W(M;7M01=@[KDQB&@K/CHGI!Y569=%A(?T-5 :(,/0U]>V_+W'?8X3RECBGAL)V1M%Y7='N[D)L9]N0/0X:(K"FY!/KM3Z^1)E;]; M2DZ#B4N8$5,5,;CY3TR=;[#\,,1[.$/*&\IQ,F,O).E4+&P3]_(MY_MZ$1&F M1(RQLL-CH)5&( !H@2:?HV.V8S\O23P)<$>9*U_#!+^HFB$$0+ 4!P6RMQ+@ M[":L.]F?^.:P0?IJ&(@;) + +Q6'U^5MZ<9 B /R#%-(O&^%C&2/42N"<49C M6K('Q*B.=4*Q5B#3"%_5;B;Q?*MXYNR0UZ/DC;-\C6; )*['*PDH\R&K@M/H ML&>[]4"Q>:(C4229$V<"_#%S)8:=@/1#NK1 ^H<0=1K@S)#J8P(>,GZ5]$L/ MB3W8J= ,+=1HRU8&?3YHD*#1.K!#@PF)X:-^O'%)-BQ&"O&&%**90LBSU(/O M\UIQ7R+X!7^/VZ%04E )AE"NQ]%CF8>V*MK6F]CQ,-F5 BLQ,T0$E#S&HOA, M+[3/)ICS]3T'<[Z>@CF?5='/IRD6))<6A&<;C0R'B$^?[S5_)Y-@L&DV;!H6 M(64:?1QU-X_N4TMZLVUCCE.$;[*^_!W+CKPI9DU8'TML,--2^H:==6Z#Z#>M!(NR74OT,1&6@TH+BZYL5AY N<8\L395".H&72I@B(+2C&8( M7< 9XB?0('I=PSCYC#29,&'?%BA.MH(W1Z<,VJ-H-WG0-+@$A"L$>A!.T4BD MKKZ("5TC4V'RF=Z14,_Z8TDIM4:7 &'55)@3B-ZY/FTPF$L]T=!/"XIKL-8* M]Q@KJ>F#NL=!",G0Z9^I51A5$+$KD:.G=*IS7%,_W>BLU4##IO@*MFC'-#.' M,0S*_20-@[U[E('61TK)@S]H_\/1"2HIMS"%=>,^3YI,^&N*T^1KKHA/JPT9 M&\+'<$C_7OY(76!@=;@ FC CA#_.8BNN8[$S!5ERQXSH?I<",;,F)@5:[ M7_R\_RL!;>&,NH,$ROT>>QASGC#E [X$<;) QOA\U8?;G(AZL'G+N'F#YL_( MJB%R^F )&U'+.D?DO-.N/ &=@H)K67:"X^ MY+ZU@1[FBR\'_H,2O"#*O7W^.KDWBWV*?* MI$[MN!Z"#S&9;:R 5"57F& 022@+W8S4VTVD#3T>(CM$V/T"9['3GVF=#4T) M!\Y,F,>\Y]ATS)C'73Y2;RR<(FA;FUD\%NJ?R"F65"\!KJ;RG=UY^7+]BB^JX0I$*>I*G"TAVYFH2'11NG)A MCUV-D4&UJGUC$9:NW0R[,&)M&K2&!TUXDX@&;%A9'@G+%B% M=TCK$,+I2)GJ@$GH(J,K3=X+MDS4\T6$I-'< ))KM?KWU/Y*;;#8K<=^2E$# M>Z0I6U*WEEQQ/\)P/#.8":Y@N8'E!0Y#V9WA'A:3HVI'?+ I$/D64Z=BRL1T MI7P &BOI4,CZADOT9#M9<&-X49S0R!PPH>G=TMAPM6E%/0_VFD38,RS?I.N+ M];U!7;=/2_\(XVS ^6E\,A82RCA4ZD[U0\S3!#Y0A@4&'I)X/[["&KU *.]O M?(^)J\9<]7V4IW@$OPS">W3Q7X:$&N[82Y;2E[ILCM5EA-2]Q(I5D/.2;S-Q MY' E?Z^+W'!U<@C.DON"4(6W-CS6J/0;WBL$_=\1!HW'J%U:3\ON)#X:6"FS M68GQ_#;-?VG@9NJDO)H'O#;% KY+18.;8&;V9C67.E,$*=S%MEI+)VI>!6O[ M_0TMX1E6UAHNU;:8@YB;!L&94600X\9;?.!;J&/QX!&8$+0(R72DD#NW'Z2) MEW8]T#CAI8*>BEG32P2=J$0;6UA&)-Z1AH@YT'&#QHK0]Y($=%YW<#U/@:1/ M/)#TMWL.)/UM"B1-@:2/7BR067?'M>J1@LN2:3 8.IBD9;5@.D/7(H4U47:0*-DP5>GYA"CL[ M"&+*/9FU8D>.4MK#"\1[??""XF.(D\P&5Q.!KUI?<&I5R$KJH3_JRB<.A5\; MW-G$$M+LGDTZF<4>AVE_7C_@]!#\A'T?7<6+1=@0]UJ.Q M4-O$Z4X<:]>7C!PN/NA1/\I)4=[J&I$B$NU2PK@+4H 0'P%M$QIE$9B1]-@% MZ(>8&H75/JA@("%X&6QXA/7]NRA9GAZ@4" EGV7H,_:?H$64, M MI-@;8.(]K1VKA10.@=@'/76::E69+D5 ,!B4D5,$\V+-S[@H0#;L)3$J\&P:E:S6_F"<_'8.QP2 MXM+**6P"378;4&F-B0'H?FG8CL(Q.^R=Z>M%>ZT1=3)^A&KO3*T-V',%FZT" MV>6DO (^0X"'75 1:-,5V.*DXUM5SC3:B[N!P6HWI#\T3PN*P (S-RO0;&$] M-9P6L%5!H]%/PPSYS_1"NEO9U+CB LDXS>Y]LP%A4V(OY3\<=O].+["G^[H+ MY5QL*=V:37.A+N<+$]"D4K,'A-^(EU!!8,)E06O)W4(=%U!=EJ)1]\ M&#PP%P74([4@/03<8EWUP. P"QRVWUX5%I$ ]2Y-Z ;C'&?V1)CCCO).>NP' MP?? "%*5D=&CV4FBA&SX\@Q3;J!TTQ>/;2@MP1A.JS'EUNLH8^ M()"'"FY72.%MS-D(::4NEJ0NR,T1S(>2CJ(8'@5AN0%I5IFHW_"\JQTFH4J$ MGV "M8*/K@ZI'>,LH"1<5?7U(7I5#CF^%J!0!+P/E%?JT_5A84$NF!$HL3F" M42\)B1I&JPC'37K;D$-%Z"AJ[(QZ6HG-31/?MHVA%BPVG!QALZ)'B!Q$L$S' M_(US+'#W3$CO0'2$0T;!35Z(=X\:[Y+E05NKWRNS)L,C[0:_$Q8=GKRRZ-)A M@XCR(.C]<)"%TUW^F6JW'^M*/I/ R;-[#IP\FP(G4^#DHQFS0""NTD!32)XTDT MC2&0N8>S$/WEN[3Y"46/3$X 0^3O2YZ9U_DFIFAJ,5.PWL+(34_G6V+35 9Q M0VLE0+0)HHFSF-*!)C7Z E#/R9V^UNP)PU9)Z%03<-5QN7T8-EJSHFN%O$G4 MW1UVI[$4E(K^]$&9P6*\V0$6"\-4E+A"2N/<<>/DOI\KQ:(T>P/[9I^$H)2^ MY8Y6,I*H=O/I[0,1[@\[;(6??NP[ZIX+V8T\@-1/(=AFV=WY+(F7+\%T_,Y]H!&!8+< MW51JLK)FG>90IFD5$GT.R2+44F%G^>1V=VB=,YAZG4Q,LIE.\4B=]4'M'=VY MTDZG^36+^]9V+]]M;C@!_0S(0K?]66Q>G_ 5!+ P04 M " !/'-DS5?! M;MLX$+TOL/_ ZD[3&$A4I MD1O9 8J>3)'O<=X,A\/Q^=O[(B??I77*Z&623J8)D5J83.GM,OEZ3=]=OU^M M$N(\UQG/C9;+1)OD[<6??YR_H?2#U-)R+S.R?B WNTIGTEZ:0I+/QGJ>$TK. M6#ICL^EL1F:+T]EB>DH^?Z04Z?<]=Z M.D).7PH",M\7T^Q^QNK%",VD&A8-"T'SM],(%:;2WCX,PYO%GIM.B3T!4:(' M%)6UD';[MFY6>Q1Y+W;#<%SI095>E[WXX<1$F"(DYO0LG26$>V_5NO+R'V.+ M2[GA50[QJ_2WBN=JHV0&]R*7A=2^!^@L>VZWTG_BA70E%_(%@_$&J**$JT+T M(&U?_M?7YLH([L.UW4O!+QIY%*=H.J,GZ01,)^Q@#7-F30[))K=XY\?IR*WM ML5#%'%6D?QVC8O@"CA'297ZJB8=KV7>MAP2XO?@PHCAZ70B.<_]5OC^K(B-S M,1+0[-DQP>Z6HU'1?B3@D-;#8RSW*]LHVUU*_#CDO/<4RW%9UL!Q<+3-)R5W MG--=3OMUM(1.&1]EOL6'4=]L8YAK;7S8(TKA9:GTQN G/KJ+^/)^D1L2FH(% MMP++U\];!U9:4TKKE73=QSMLL+-RLTSP!:"Q^M_F?#V!MRE"GAGH5_%0/H$B M\ZM'>9&+=WJ9.(AI+NL0_TI',KDYU!&@**WP$'X[;THK#_4&* Z: GZ8/TB] M@26BH(6%U]F'SH)F1E1A ,TVA5_E'RBFIRW"_@E!WMV6O.5D]F_^B*,!<]%E;=1 M;4@-8HC0SZJ7\4_/[1F#]0XJS#PI&&RXI#1M(N%KYRT7T"1Z6T':X5'C6=W& M $%\ZO"LND>,57&9O(!1.90#3,YZ:U>!+>4K7/U@307=;O@SM5"0 M"9AB2L M9T 3_+5;P3RZ!6D:9N&2*)/=!%Q6V=H,:YVLZR]\_@!02P,$% @ 3W.L M5+Z0.GZ5! $"D !4 !I;F)P+3(P,C(P-3$R7V1E9BYX;6S-6M^/XC80 M?J_4_R%-GT,(N[1==-P)L7LGU-U;M'!JU9?*) -8Y]C4-@O\][7#CV6/V#'L M)LH+A/C+^/O&]F1FQ(=/ZY1XS\ %9K3K1XVF[P&-68+IK.M_&P6]47\P\#TA M$4T0812Z/F7^IX\___3AER#X A0XDI!XDXTWGB]I OR6I> -&9>(>('7#J-6 MV&JV6EZK<]WJ-*^]X4,0Z,<)IM\[^F."!'B*!A79SZX_EW+1"(">F%Y=9=CHYN8FS$8/4('S@,IH%/[] M<#^*YY"B %/MDUAS$;@CLIOW+$8RUI<.H)3&68X#3<84)$B"*<69ASF!J)[MVGYV_KF7\]>E)N M%FH;")PN"/CA6RDE+$68!BFD$^ 7DLNU\ZX_$M4S83I9-&*69@&LV5:1+*.J M#KX$-8M4:Q@OLPL5'0/UC>5&!88IXVD6!UY+T-:"O:6,Z]F&#!J44DRQ!MZK MGSNLIEJ*FBT)6$M0X?XH)!$6GRR9V"^Y@+@Q8\]A EC/'_UWK2^#[>5VX0#_ M>Y=->OOJ9! T =+U3<-;-D1'7L:/?%(MF_S-5@JKV]TJ#5Y69HPF!'(8%D&K M9:GV)@S45A-N3$_@);*]AQDBV_7LK7$>00.B @^.U106CQT/5\!F"!RSY(XF MMRIJ6&CEXDH_JT\PPT)R1.57E.;1L\%*9S=0B35?,)YM[Y$.NWVVI))O^BPQ MDW5ZJG3NGS&!K\OC].J$Z"FD=%9CM!XD^DTUQ=O,NX!B ;YTOKTDX2#$[DM' MN,C(U8*MBF=?73[R,5N97W]&9%4-M.68E:H!7Q7;(5+I%_L$+ MZY&W@4MDJA>QQP$9N.4-E_E.5D;)<,ZH.>Z8("6R^HMCJ1+?/DO3)=T%D;Q\ MP8HKD=^($1RK4H#.'M1&YQB1'')F4(G,AART-T"=NBQOT=4#?YQ.V&%P= MTX$02^!G\34^4GJ>*TP+1C3'06-$EPNFN*7-Z5FG*6V@L75E12JRF*1$3O+N)U%7V1BOQ2?*^FBD6Q],Q>%!76 MYLRA\'Q1=9FNW4U&):SE'Z7")>FS=&%!7#35+P]Q:!^Y"*M?)E+4>G)15;_,P[5=Y:*N?DG(>Q.@=TS0"!;AX#SY>[GGVY^<=UOF&#J,QRBX0<:O$U)B.D] M)!CU@#(_1B[Z[#6:7O.\V43-Z\OF]?DEZCVZKC@]CLB_U^+'T$\QXF605'Z\ M==X8FUQ[WFPV.YL/:7P&=,Q3G%]XRVAG$2Z.AFQUPF;P9R\[N K=23V[D+&- MJZLK3QY=A::1*I G;7A_/G;[P1M.?# M!'B MD[L,<\4NM]%T+QIG\S1T5L91B/$+'B'Q^_6EHU6\\D2$1_!8M*GK#W',*Y8I MWB@>J<^+*\D_*D%3_A$Y.QG?!4U1Y0 M)MLML51ML8CI\JU%F$A7,(A*M<60O9$6SQGF,]#&*!E#L%-^NIPI4AR'= M"W$D9JC&?Y=BT\TV9?7\XS\/A$7L@T]J?D26E'%KV62C:[;+.-"CAAK%>WT,P33!A'3("FLAG-#[:X [#B:KQ9<(K4E"4 MTC022VVT(8Z^"WDD]>T"4LIM:^!3ZJB*FP#!CO(C!K46QKR%$=;@B$YLI3%,@YQ4A9K_G M2J=@GP7FWK#R]L2]-R#ZY:LNI.H[UJTTQE^R"CTD!>M8EVA=@S)V&.OW'S1B M#),V),F4+)8_JM>KA7$5.Z_,9;K]"U&45[6*0+&'4-H<8S#T(8Z"B$5D_,B? M06CDQPH2]$$5,=A-9)J!M2):2EH%H, Z*.>)L=;W*!;(85Z_?&4G_BB+/H]& MRAE@?W!%%/0)32/!E=U@0QIEVDB*6X6CA*E0S2U;L'32=(II)62TIQP'SDY: MZ_AD%?QO*-+[K&9ICX&&EY\/":9C/O9]HS!C;[RNB4\^M.O/PNB#%J#*C+96 MH$MQE*FCA7P-"]!B8Z&B8\:8:7%@0P'MU]@?*RA1'J_(12Z':1)68DBH66V\ MVBO8:X+A :'-1:D?=_AP-/\=ZX<"3=Q!@\!6+ENW_T(625W$A6NX\74V0FE_ M=GC8N(@NW[I;[XJR_Y;B>WX 4$L#!!0 ( $]SK%03QTE2+P0 /\H 5 M :6YB<"TR,#(R,#4Q,E]P&ULW5I=;^(X%'U?:?Y#-O,<0FB[NT7# MC!#MC**E4U08[6I>1B8V8(T39QU3X-_OM0,L%7'B2AND^H5\^-CW^/C&OO>* M#Y^V*?.>B2@HSP9^U.GZ'LD2CFFV'/C?IL%P.HICWRLDRC!B/",#/^/^IX_O M?OGP:Q!\(1D12!+LS7?>;+7.,!%W/"7>A N)F!=X-V'4"WO=7L_K]:][_>ZU M-WD( M6=T>QG7_W,44$\H)$5^G'@KZ3,^V&XV6PZV[E@'2Z6,$3W*CR@_3U< MM6)Y[' *O@G+QB/T;.C-E<9&M[>WH6X]0@M:!81!H_#OA_$T69$4!313FB2* M2T'[A7XYY@F26LC&*7A&A'H*#K! O0JB7G 5=;8%]H_""<[($UEXZOKM*7YA MD6;SO)/P5.O>O8$%4*@0^$J2DDP&F"=K?0.+&L"5RAW,9\%%JNG#E+2-E2"+ M@:]&"PXC*1+O7SV0W.7@-P5-[_1K%_ZW+#,T9J2#7!+TL M2_!,$H.C5G6PUMG%0UEG-T#;&ZDQ8T/)P;J#8@&^=[Q!C.!:+_47M)I&1:PWV4CQ'@!7Q#$#PN31C+!CHEUCS F"Y]]!/&"X(' MOA3KXVZ,1'*67[\<:(\(LHM M>6"C6%$2LYKMR0 MX]6U#2MQKET2QU1/L5+BQB4EK,HV5K+\YI(LC14B*TE^=U 24SG*2I _'!2D MMNQEI;*J9V M8C@2GMH69^U$<212?5T%V$X:IZ)5BUJSG2J.!*PU-6X['9R*4VMKZB?UU/!, M$ACXY\=CB_I1_ZV#-_\"4$L#!!0 ( $]SK%0B41SUXA %:O 3 M:6YB<#(P,C(P-3$Q7SAK+FAT;>T]:W/BN+*?=ZKN?]!A:W>3JA@PD ^RX EJNR-' M3*G''1O&4O>5XI%27B$)7;]M)BBVQD"NG\U]\$I*Z6!)0<>V_>GZ<4Q/%+S% MC!6@DP*]F.!&])[O*MBT(OZ(ND/Y5M0B::\4U=CD?$^P\<85J!:@?36Y3?W4 M_HS9 M@A[+9;A_#9+TEW+@K162_4!(O!4?\_OY6+G-_=[$MTTF3&?*$F_W6N=G'.8[ M=O.&,XVM[,/6=;Y66]R#B\GX^G6"!KE,WRLQ1AA3.EO+!]BPABL-Q[<]L5@/ M(6Q,,(/8P#4">48]NL5DW-C 8]Q(C&KX0C#;V(1'V)IXA\#4J\6J6O[[ MZ%L>]/Y)(6B"/O]0%-(4C'K,),,% 0XB74=XU"**4O]T,F4>)0A.8=]]_N-S MKNG8'K,]90!\GR-&\.USSF-SKQ!8E$+]I!!@<#)TS 5QO84%;#J"KLJ(3KFU MJ)$_O_N.=SS@4^:2-KLA/6=*[>#A'I&/]X@+(C4Z)O(]E_\?JQ&U./..R92* M,;<5P<<33SZ;+Y]9;+1\!(OB.J)&J.\YQT 4D_^(4#&Y.[,HH &ZD^7J__/I MA,]KB#(3T1=NFLP.OT"O=B#@P7SG7@_-I8D4/_J2(S9%,01VKS6FS#;A/^_, MHN-DS-AK5:-&%002T=Q'[^A2UR]2)(95$]V"]6[@( $(7; MDP ;SI!)F8L/4"?67"G0 )=(TU6;2"\ V46)F"D/=C87-J.F^YQS^71F,5SE M$$IR8/G =7P1?I=VO19.D7!S-<55*Y,S7'WG)CX9<2:(1)&M-=Q-_4N2"K=? ME@BNAS #0CGFZCMH-.&U0 ;JB)Q2W%?44O3NJBV&L+FA<]2R KT"54C00B[3 MDH0QBA42O%@ MH7/3W'VW;(DU0A\(8?Y$CY"U!1J\3$\-H!L3*#L#.O7;7V@ MM4A_T!AH_9/"L!Y@MAFQOVZA]-9U3Q_H6I\TVBVB?6U>--KG&FEVKJ[T?E_OM#\\E?[=Z%_H[?-!I[U' M6OEFGH!*J50_-$G^OOWG0U,#Q.BLT[LBCS.(+;#*/ZN5QIT94]K#TA/ZW9Z@U2@U+WN]:\;@-.@0T"9#T!C$[5,.CVB M[N^8NZ1S1@876BI0C=F:I9UI- >(HEHM5U*!8XJ8K04^"M(F8#:R$WW7&KU+ MH.& :/]:\:+6VJU]:-%\B/(-DE00&\R]F@G^[10Z34RZ6# *KO\ZY=R5;J\6 MN,.Y^A5=$%7=(SC@73W]@:F?^0./9,7;@7&/C;F+F52O#2W2']#; ^V\U\!X MY53O="\:O:O&'M';S?QZ-R$%,]_1OJ)";S>N0LUUKO<'/;1.C3[I=[6F?J;# M=/0VT0=] B8 %%=O]V,SBSNC=@1=]ECFTVO^#,)N@[KL\?H--PHPYO?83#@_ MD-N2"B[@.MTV'#%SA,S<][%W,\A%-ATS8,(6L^@-:,?U+(>XIX3S9$B/;D\' MW)T>^2=X&OV6'OA#P(H@-IT>&,H&/D@MQVT?+BQA /HE_DV$)AX=6@P6Q+)F MU#2Y/?Z<*^;D=^ 2(_H>3CJ^K&HY?_#',;GAIC>ID<-2_NB/<)&YC5DP[#4/ M66,++)6K?_KMTV^_G7B8U:V?>&+;/(L <'PS&O@'$QXWJ!4Q[92;IL66,ZZ4 MY/RW#/Z%A7%S*+R&39Y@#\^XQ>"%(1-RT*+ K5!W2NAXEG0]J$V!*42DJI4CRL'.X_? W@4\C/3,JVN<8[J^PL.=,O M-=*^OCI=.5*9$.SH^5Z^GR?:5?>R\Q]P!_06A,K@?#:E_2?M3GX-L4)N_02? M@6TH2)N60C\AM6%,PS0%<]WPXY+;3 V5QSZY=.PQ:?Q@MK_!FTS#G(?/F783 M_KZX.#[<'/M;/<>E"U^M$,?(B)=^8[H0D^.-0Z(#9+LGTRX;+$. MGT.>XO5TH%2/%(/4LV!.ZOLR)^_'Y74P^,^&6B76O>BTXXLNDSW7%ZW]/8Y M:?2T!FEV6MH'BE[?"FYSPHQOQ)LP0F>@;F>"@SXE0V=.ALQR;@@?R<8S4,_D M2/E"1K):C7"7<"PD,IE)/(>X?.I;'K69X[O6@KC@4;NCA7PS?,$9 E3I:!,G M&%(L\X!$UL81:B^BMI%C 7!\#TT =^$UEX =7F=)W@/0\>QAA1X""8XCRO1?PON =LVG>G4 MM\/(S\7%JQY6*L<;'+6'11D)&E4/,09[/2*%\P+JQ"=&9KYP?90PD-&>#PQ9 M >\TD#84LSXS?'B1 Q8-PR,[ZB%IGO5(J5S,0\=?(V[8MJ"5,C%[OICU'8L; MP%CV^ K,"=@4ZV5D[/ U*;2:%'@^P:SN"IA:H8I:BLF8-CL*AI8,:WEE?17Z8Z(S&F%PL'UQ.WI-.L'4%",V MMWLMFUHQE=+.TJ$M,-N(VN+2P]D$:OK@?.;&W,) MB!BS($0$$;,=&3#Z+I.] &:X2XUG#;@,(H,3_KB($I:U0. W'$#C^MLP/V@1 M[ =WX3T07&H;F.NGAKR^!#OCA2HF%:8;[$^;ZZ/5@*QJ>8>N#5GSR?KAD!?> M9NTWU[U_%%Y\OW"K^TG /RNSDJ'KYUSW_/3+,E>12$\D[FV)N1?1[2[P"%R9 MY%CMZZOE8&O\CWC^XPY2DV6,TVV<:\II3VM\41IG ZU7(]2ZH0LWEG)K#A>MWMHYR%7\R0SN M+<"Z;V4?X<\A+N^9D3>>^]$]-B6E?+&4)SWF^I;GHK[M@)X/4]6@K&ZH5$.RL9<"./(=Y\*T!$DL.%75!@34@Z/)>=) T1ZMBP:2T("IW;D"YN[ M$T0#_>$)'W*/5*MY%=2"8&"GD2V@'WX#%X,OCP@&-VLM[TG"4CRY>YP/A2[!)W HZS=-N&# (E\ ;-B*E&W&)F MR%*2,\#)FCDND^*]W!(X>F#TLX=L0*5986@8GX;$ M\K9?N8?Y1 8KB%[Q7$H%UF0R#TD(3B[ =F?,P)-/221<'Z2+AGBDEL%?SH+L MYXO[H%2B*^%<7&V,$21EW6CM0TWWETNPPAM710-6-]S,F&PT)FID3&+T(_[, ME** =B"B)%IF'U@=%7- 5=+%JBM4SD1Z>;@*@29A,E(+I<[=(TO]LD>&OB<5 MBL6GW LJE,\< :Z@#1"$\&$>74'A18,%OD$#PCKE5/ A$PO27981GD$-60TY5DXIQ" 5'-Q&Z56 MGFVC)"^GE1M?3H2K^:(:X+!R]^01H4"@)5\%1'XK>5V=6GT3\'A14HP"'X4_ M$MX?N(B!%(/$K!R4P&2O[#4TPI>E#[DGF0>UBA37MZ\W^"7J'%ZIM.$A:8E' M5ZK=WCS:[J%JU/%/V,%2MXI$M+2/1J.ZW8WX$TJ"NVS9_._R8:6T?XB7'B^Y M"'/L"C /VNP:"T09SRYM]!I."K2>PNWRUSN6O\TZ0-29S]IU?9\\^VI%J[=E MX^ ALM&5R9!>F P)W,YX8B>0D!27EFQ9V^)]TQGCS@*U"?!(EXZ93.[)0.@' M(RWJ48*7T9 =-ATRTTQ&,[K\E0B"/Q-!S/#.P-VL5""#F\'-X&9P,[@9W QN M!C>#F\'-X&9PT[QAE^X",$55LNJO%Z[^VB)WR>K"7_%G5%YD:T_[>J&?Z@.B MMUO:5Y**BH#WLU_SOE*23TX'OL^L9!*/=YN(?K5=@V&TY_WL.\.WRV^O18 U MIQB>-OU?==L(?]'"-02?88E2ZB\M?W'="CX>_H;'YUPIEP(]&Z-\5H60%A.T ME2J$K/3@_98>9+;K%RMY"$B8U3UDZCVK>\C@9G SN!G<#&X&-X.;PEHJ][C&1<#D=];^((F+3Y]F>"G_SKVJ52_FA_]?/:^Q7\S8./ M=)]VI;C-VTU_6M+SZ%S>P39Q>Z-,_+"NMP?:>:\QT%KD5.]T+QJ]JX;\Y<)\ MZC=8M\HK\7P+>H!T.2.R3,VH'Y1L3]=U.ZY%Q-K"1).N,D, M)[ANKA886MPV0!^)UPMN@;2X3K>>34:*<&[N/L3L/KEW M:S975\K1=NS:#T"O$$8R$V]JU?\?4$L! A0#% @ 3W.L5$8&V3ZP$P M/RT! T ( ! &5X7S,W-#(U-BYH=&U02P$"% ,4 M" !/@, "\. 1 " M 6@X !I;F)P+3(P,C(P-3$R+GAS9%!+ 0(4 Q0 ( $]SK%2^D#I^E00 M ! I 5 " 1$\ !I;F)P+3(P,C(P-3$R7V1E9BYX;6Q0 M2P$"% ,4 " !/8,% #1-@ %0 @ '90 M:6YB<"TR,#(R,#4Q,E]L86(N>&UL4$L! A0#% @ 3W.L5!/'25(O! M_R@ !4 ( !CT8 &EN8G M,C R,C U,3)?<')E+GAM;%!+ M 0(4 Q0 ( $]SK%0B41SUXA %:O 3 " ?%* !I H;F)P,C R,C U,3%?.&LN:'1M4$L%!@ ' < OP$ 1< $! end